Pharmacokinetics of tiotropium in asthmatic children aged 6-11 years support its safety profile.

08:00 EDT 4th July 2018 | BioPortfolio

Summary of "Pharmacokinetics of tiotropium in asthmatic children aged 6-11 years support its safety profile."

The efficacy and safety of tiotropium Respimat , a long-acting muscarinic antagonist (LAMA), as add-on to maintenance inhaled corticosteroids (ICS), with or without additional controllers, has been demonstrated in children aged 6-11 and 12-17 years with symptomatic moderate and severe asthma (1-4). The pharmacokinetic (PK) properties of tiotropium have been reported in adult patients with chronic obstructive pulmonary disease (COPD) (5) and cystic fibrosis (6), and in adults and adolescents with asthma (7), but not in children. PK evaluation was intended to assess whether exposure to inhaled tiotropium in children aged 6-11 years with asthma is within the range observed in adults in order to further support its safety evaluation in this age group (7). This article is protected by copyright. All rights reserved.


Journal Details

This article was published in the following journal.

Name: Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
ISSN: 1399-3038


DeepDyve research library

PubMed Articles [22776 Associated PubMed Articles listed on BioPortfolio]

Enamel defects and tooth eruption disturbances in children with sickle cell anemia.

Sickle cell anemia, a genetic disease caused by a mutation in the beta-globin gene, can present oral manifestations such as delayed tooth eruption and hypomineralized enamel and dentin. The aim of the...

Assessment of the Effects of Age and Renal Function on Pharmacokinetics of Bazedoxifene in Postmenopausal Women.

Bazedoxifene (BZA), a chemically distinct selective estrogen receptor modulator, has demonstrated efficacy and long-term safety in phase 3 placebo-controlled studies for prevention and treatment of os...


To analyze the context of drug use in children aged zero to five years old.

Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11.

Currently, there are no interferon-free treatments available for HCV-infected patients younger than 12 years of age. We evaluated the safety and effectiveness of the all-oral regimen ledipasvir-sofosb...

Opinion of the Scientific Committee on Consumer safety (SCCS) - Final opinion on water-soluble zinc salts used in oral hygiene products.

The SCCS has estimated that exposure to water-soluble zinc salts via toothpaste and mouthwash at the concentrations of 1 and 0.1%, respectively, may lead to a daily intake level of 3.54 mg for adults ...

Clinical Trials [15855 Associated Clinical Trials listed on BioPortfolio]

A Study to Evaluate the Safety, Tolerability and Plasma Concentration Profiles of MK0633 in Asthmatic Children Aged 12 to Less Than 16 Years (0633-019)

To evaluate the safety, tolerability and pharmacokinetics (PK) of MK0633 in adolescent mild-to-moderate asthma patients to permit further clinical investigation.

TMC114-TiDP29-C228 - A Safety Study to Evaluate the Antiviral Activity of Darunavir (DRV) in Combination With Ritonavir (Rtv) in HIV 1 Infected Children From 3 Years to Below 6 Years of Age

The purpose of this Phase II trial is to evaluate the pharmacokinetics (blood levels), safety and antiviral activity to support dose recommendations by body weight of darunavir with low-do...

A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years

This trial is conducted in the United States of America. The aim of this trial is to investigate safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pha...

Pharmacokinetics, Safety and Tolerability of Fevipiprant Delivered Via a Once Daily Chewable Tablet in Children Aged 6 to < 12 Years With Asthma

The purpose of this study is to assess the pharmacokinetics (PK) of fevipiprant (QAW039) delivered as a chewable tablet (CT) in pediatric asthma subjects aged 6 to < 12 years with asthma. ...

A Phase3 Study to Evaluate the Efficacy and Safety of MEDI3250 in Healthy Japanese Children Age 7 Years Through 18 Years

The study is designed to gather the efficacy, safety and tolerability data in Japanese children 7 to 18 years of age that would support approval of MEDI3250 in Japan.

Medical and Biotech [MESH] Definitions

A species of RUBULAVIRUS associated particularly with acute laryngotracheitis (CROUP) in children aged 6 months to 3 years.

Nutritional physiology of children aged 13-18 years.

Nutritional physiology of children aged 2-12 years.

A person 65 through 79 years of age. For a person older than 79 years, AGED, 80 AND OVER is available.

A person 80 years of age and older.

Quick Search


DeepDyve research library

Relevant Topics

Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...

The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...

COPD (chronic obstructive pulmonary disease)
COPD (chronic obstructive pulmonary disease) is used for a number of conditions including chronic bronchitis and emphysema, which all  lead to the airways in the lungs becoming damaged and thus narrower,  making inhalation and exhalation harder...

Searches Linking to this Article